Disruptive Pharma is a pharmaceutical company that develops novel drug products by applying a unique drug delivery technology. We develop selected drug products based on our proprietary drug delivery platform, the pharma-grade mesoporous magnesium carbonate (Pharma-MMC). The Disruptive Pharma company has offices in both Uppsala (HQ) and Stockholm.
By a clever combination of already approved active pharmaceutical ingredients (APIs) with Pharma-MMC platform, several unique opportunities to realize highly valuable therapeutically equivalent or improved drug products emerges.
The Pharma-MMC drug delivery technology can be used to create amorphous solid dispersions of the drug, hence increasing its dissolution and the body’s ability to absorb the drug, and may be used to rescue particularly difficult drugs or to enable novel product formulations
Disruptive Pharma is a spin-out from the company Disruptive Materials that is located in Uppsala. The company is well-positioned to exploit its pioneering discovery of a unique mesoporous magnesium carbonate (MMC) material. Up until breakthrough discovery by the group of Professor Maria Strømme in 2012, commercialized by Disruptive Materials AB in 2013.

Pharmaceutical

Disruptive Pharma AB

Maria Strömme

Jacob Palmstierna

Malin Vågerö

Sven Undeland

Jonas Fagerberg

Stefan Ström

The Research and Development team at Disruptive Pharma AB is responsible for pioneering the creation and optimization of novel drug products using the proprietary Pharma-MMC platform. They work on integrating approved active pharmaceutical ingredients with the mesoporous magnesium carbonate technology to enhance drug dissolution and bioavailability. The team’s expertise spans process and formulation development, analytical chemistry, and project management, aiming to produce therapeutically advanced or improved formulations.

Research and Development

Leadership Team

Research and Development

About

Team members

Other teams at Disruptive Pharma AB

Leadership Team